Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 138.09M P/E - EPS this Y 57.40% Ern Qtrly Grth -
Income -20.19M Forward P/E -7.04 EPS next Y -85.00% 50D Avg Chg -5.00%
Sales 2.7M PEG - EPS past 5Y - 200D Avg Chg -23.00%
Dividend N/A Price/Book 0.91 EPS next 5Y - 52W High Chg -75.00%
Recommedations 3.00 Quick Ratio 140.77 Shares Outstanding 40.28M 52W Low Chg 91.00%
Insider Own 10.17% ROA -10.57% Shares Float 36.43M Beta 1.75
Inst Own 10.35% ROE -13.77% Shares Shorted/Prior 450.03K/501.39K Price 3.45
Gross Margin 100.00% Profit Margin - Avg. Volume 864,170 Target Price 3.15
Oper. Margin -996.23% Earnings Date Nov 8 Volume 460,205 Change 4.23%
About Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's product portfolio includes ORMD-0801 Type 2, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes; ORMD-0801, Phase 2 oral insulin capsule for non-alcoholic steatohepatitis, a progressive liver diseases; and ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Oramed Pharmaceuticals Inc. News
09/22/23 Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company
09/21/23 Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company
09/21/23 Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.
09/13/23 Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder
08/02/23 Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally
06/20/23 Oramed to Present at the 83rd American Diabetes Association Conference
06/17/23 Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
05/30/23 ORMP: Advancing Development Efforts in China
05/18/23 Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit
05/15/23 Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China
05/01/23 Oramed Appoints Ben Shapiro to its Board of Directors
03/27/23 The past year for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable
02/09/23 Oramed Pharmaceuticals Issues Shareholder Update
08:05 AM ORMP: ORA-D-013-1 Failed To Meet Endpoints; Ending T2D Oral Insulin Efforts
01/12/23 Why Oramed Pharmaceuticals Stock Is Crashing Today
01/12/23 Oramed Pharma Shares Sink After Diabetes Candidate Fails In Phase 3 Study
01/11/23 Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes
01/08/23 Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
01/04/23 Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes
12/21/22 Oramed Letter to Shareholders
ORMP Chatroom

User Image Iwillbuy Posted - 4 hours ago

$ORMP Fuckkkk this Company, So corrupt this market is!

User Image StockAutomatePro Posted - 2 days ago

$ORMP Looks like the stock is about to take a nosedive based on the chart. We alerted the SELL signal at $3.04 and we were able to close this one with profit at $2.6 💯

User Image quark_n_jaguar Posted - 2 days ago

$SCLX $ORMP Translating the Oramed CEO's words below - "we were suckers to get in the middle of this. I hope the investor committee outside bails us out on this investment" 😂 "In our opinion, Scilex has great intrinsic value that is not currently realized, based on the company's growth trajectory, commercial portfolio and infrastructure, and its robust clinical stage pipeline," stated Oramed CEO Nadav Kidron. "We believe that this Senior Secured Note, along with the warrant package, is a favorable outcome to Oramed while also supporting Scilex in executing on its growth opportunities."

User Image Ferrari360 Posted - 3 days ago

$ORMP WARRANT DEAL is we can buy 13 million Shares at 0.01 per share

User Image Ferrari360 Posted - 3 days ago

$ORMP part of the want deal is we can buy 13 million shares of Salix stock for .01 Cent per share

User Image Ainvest_Newswire Posted - 3 days ago

$ORMP Oramed Pharmaceuticals climbs 12% premarket after securing $101.9M senior secured note Deal with Scilex

User Image Ferrari360 Posted - 3 days ago

$ORMP my opinion of the deal is we're going higher if you don't understand what the deal is you should not be in the stock market

User Image marvessa Posted - 3 days ago

$ORMP opinions on that deal ?

User Image Ferrari360 Posted - 3 days ago

$ORMP with the latest PR I am delighted I loaded up under three bucks 80 years old and 59 years trading stocks give you a sixth sense I smell money here we are going higher

User Image b54 Posted - 3 days ago

$ORMP Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company PR Newswire 6:11 PM ET -- 18-month loan with interest rate of SOFR plus 8.5% -- Oramed receives warrants to purchase up to 17 million shares of Scilex common stock -- The Senior Secured Note with Scilex replaces Oramed's previously announced Stock Purchase Agreement and DIP Term Loan with Sorrento Therapeutics

User Image Rajreddy1240 Posted - 3 days ago

$ORMP what happend here ?

User Image CallMeMyB Posted - 4 days ago

$ORMP Nothing but a scam. Useless technology.

User Image FlipStink Posted - 4 days ago

$SCLX $ORMP Why is Oramed getting clobbered if they are getting saved from investing in Scilex? Or does this indicate that the Scilex bid is falling apart, and Oramed will be forced to take Scilex?

User Image Iwillbuy Posted - 4 days ago

$ORMP Stay away this one smells rotten! Management not transparent and preforms questionable acts to its investors!

User Image CallMeMyB Posted - 5 days ago

$ORMP Their science project failed you guys

User Image Iwillbuy Posted - 5 days ago

$ORMP what a fuccking yo-yo company! Can’t be trusted!

User Image quark_n_jaguar Posted - 1 week ago

$SCLX $ORMP Can you imagine what will happen to the price if the SCLX dividends were unlocked now? The auction price of $1.5 from ORMP for SCLX will look terribly over-valued, as it should be. Like someone said, Oramed executives+lawyer just got mugged in that auction. :) Hopefully they learnt a lesson on where they should not go.

User Image Ferrari360 Posted - 1 week ago

$ORMP thank you Bashers and shorters for the cheap shares and the three bucks filled again🎉🎊🎉🤗

User Image CallMeMyB Posted - 1 week ago

$ORMP Still trash I see. Below $3 now. Not looking good.

User Image quark_n_jaguar Posted - 1 week ago

$ORMP Hopefully this document (and audio recording) shows how Oramed management completely messed up this Scilex deal. They are throwing away money getting absolutely nothing here. https://cases.stretto.com/public/x228/12086/PLEADINGS/1208609132380000000038.pdf Even many retail investors knew BODs of SCLX and SRNE were almost the same, and something like this (the non-refundable deposit of 8M to Hudson Bay by SCLX), and the quitting of it's directors, and the other financial obligations mentioned in the call as reasons Oramed wanted to backout. How do highly paid lawyers and managers that deal with millions not know these simple things? They just had to literally google Scliex and Sorrento over a few hours to know the history and what could go wrong here.

User Image Iwillbuy Posted - 1 week ago

$ORMP Fuucckkkkkk this company and It’s management! Will never trust this low life thieffffffing shit again! Stay away, they don’t address anything here and they are not transparent with investors….

User Image Last10K Posted - 1 week ago

$ORMP just filed with the SEC a Financial Exhibit https://last10k.com/sec-filings/ORMP/0001213900-23-076238.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=ORMP

User Image cctranscripts Posted - 1 week ago

Securities Transfer Term Sheet, Dated September 11, 2023 Among Scilex Holding Company, Sorrento https://www.conferencecalltranscripts.org/summary/?id=12535767 $ORMP

User Image Iwillbuy Posted - 1 week ago

$ORMP Joker at best! 👇👇👇

User Image usernameneeded Posted - 1 week ago

$SCLX Another prediction came true. The vocal outrage among shareholders against the $SRNEQ CRO & Latham worked. The "people poison pill" worked to spook $ORMP. Expect sustained positive news out of Scilex for at least the next 6+ months with continued double digit sales growth & label expansion efforts on its 3 FDA approved products, as well as positive updates on its expanding pipeline. Then there's also bonus litigation prizes! LOL.

User Image quark_n_jaguar Posted - 1 week ago

$ORMP Oramed management didn't study the SCLX deal and are now trying to back out. Basically a horrible decision, and now they are forced and reduced to provide debt financing like Hudson Bay. https://cases.stretto.com/public/x228/12086/PLEADINGS/1208609112380000000114.pdf Too bad they didn't Google "Scliex" before offerring to buy it. 😂

User Image Iwillbuy Posted - 2 weeks ago

$ORMP What’s this dude’s motive here? 👇👇👇

User Image usernameneeded Posted - 2 weeks ago

@quark_n_jaguar Why should it NOT be the case? Delays are the MO for this D-list group of bankruptcy professionals. How many times have they failed to get anything positive done and be late? ALWAYS. The only party that's going to be backtracking are these bankruptcy pros ending up accepting the higher $SCLX bid that they rejected in court (contrary to the wishes of the Equity Committee & Creditor's Committee). $ORMP is still going to end up directly investing in $SCLX, though, and won't really lose anything. THEN, the real battle begins in earnest to either sell/partner certain $SRNEQ assets like RTX and secure exit financing that is the least dilutive to existing shareholders. If Oramed-Scilex-Hudson Bay Capital join forces, it may have a double-edged sword because the competition ends and the collaboration starts. Current shareholders need to be vigilant & team up to ensure there's a decent recovery and no further stealing of equity/assets. EC to the rescue!

User Image usernameneeded Posted - 2 weeks ago

$SRNEQ Yup. Don't expect the lawyers to submit a plan tomorrow. Expect at least a week or longer delay as $ORMP and $SCLX tussle to improve their bids, with possible backing from bigger parties. That's why the stocks are acting like they are today (along with the great RTX data being released).

User Image usernameneeded Posted - 2 weeks ago

@Gmanthemagnificent @Ottomtc RTX is a non-opioid analgesic, so it's a natural fit for Scilex's mission. $SCLX, $ORMP, Grünenthal and a number of companies could be interested in buying/partnering/financing RTX.

Analyst Ratings
Canaccord Genuity Hold May 17, 23
HC Wainwright & Co. Neutral Jan 17, 23
Canaccord Genuity Hold Jan 12, 23
Aegis Capital Buy May 16, 22
Cantor Fitzgerald Overweight Feb 18, 22
HC Wainwright & Co. Buy Nov 30, 21
HC Wainwright & Co. Buy Nov 29, 21
Aegis Capital Buy Nov 2, 21
Canaccord Genuity Buy Jul 29, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Mayer Arie Director Director Apr 03 Buy 2.22 8,809 19,556 26,809 04/04/23
KIDRON NADAV President and CEO President and CEO Mar 16 Buy 2.039 26,000 53,014 126,000 03/16/23
KIDRON NADAV President and CEO President and CEO Mar 14 Buy 2.01 100,000 201,000 100,000 03/15/23
Kidron Miriam Chief Scientific Off.. Chief Scientific Officer Mar 14 Sell 2.01 100,000 201,000 201,666 03/15/23
Rozov Yadin Director Director Mar 13 Buy 2 70,000 140,000 86,500 03/15/23
Rabinowitz Michael Chief Commercial Off.. Chief Commercial Officer Jan 03 Sell 12.75 13,325 169,894 126,143 01/04/23
Mayer Arie Director Director Nov 01 Sell 25.60 3,000 76,800 05/10/22
RAKIN KEVIN Director Director Mar 21 Sell 9.4096 10,000 94,096 46,661 03/22/22
RAKIN KEVIN Director Director Feb 17 Option 4.8 6,667 32,002 59,671 02/22/22